Tag Archives: Memantine (Ebixa)

Use of NICE Appraised Medicines in the NHS in England (HSCIC)

Summary The Health and Social Care Information Centre (HSCIC) estimates that national figures for Alzheimer’s Disease medicine use have been underestimated by around five per cent. Section 3.1 in this report relates to Alzheimer’s Disease medicines: donepezil, galantamine, rivastigmine and memantine. … Continue reading

Posted in For Doctors (mostly), For Researchers (mostly), National, NHS, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Update to Dementia on Clinical Knowledge Summaries (Prodigy, formerly CKS)

Summary The Prodigy (formerly Clinical Knowledge Summaries, CKS) topic on Dementia has been updated to include prescribing information for Memantine (Memantine Hydrochloride). Sub-topics comprise: Contraindications. Dose and Titration. Adverse Effects. Drug Interactions. The Basis of Recommendation has been updated to … Continue reading

Posted in For Doctors (mostly), Guidelines, Management of Condition, National, Pharmacological Treatments, Practical Advice, Proposed for Next Newsletter, Quick Insights, UK | Tagged , , , , , , , , , , , | Leave a comment

Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease (NICE)

[A version of this abstract appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 1 Issue 9, April 2011]. Abstract Note: The long-awaited review and re-appraisal of Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimer’s Disease has resulted in changes to … Continue reading

Posted in Acute Hospitals, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Guidelines, Management of Condition, National, NICE Guidelines, Pharmacological Treatments, Practical Advice, Systematic Reviews, Universal Interest | Tagged , , , , , , , , , , , , , , , | Leave a comment